share_log

Femasys | 8-K: Current report

Femasys | 8-K: Current report

Femasys | 8-K：重大事件
美股sec公告 ·  04/24 09:13
Moomoo AI 已提取核心訊息
On April 24, 2024, Femasys Inc., a medical technology company, disclosed a regulatory filing with the SEC, indicating the release of an updated corporate presentation. The presentation, now available on the company's website, is attached as Exhibit 99.1 to the Form 8-K report. Femasys, which is listed on The Nasdaq Stock Market under the ticker FEMY, will utilize the presentation in forthcoming discussions with investors, analysts, and other interested parties. The company, identified as an emerging growth company, has also chosen not to use the extended transition period for complying with new or revised financial accounting standards. The information provided in the presentation is for informational purposes and is not considered filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any filings under the Securities Act of 1933, unless explicitly stated in such filings. Femasys's CEO, Kathy Lee-Sepsick, has signed off on the report, affirming the company's compliance with SEC requirements.
On April 24, 2024, Femasys Inc., a medical technology company, disclosed a regulatory filing with the SEC, indicating the release of an updated corporate presentation. The presentation, now available on the company's website, is attached as Exhibit 99.1 to the Form 8-K report. Femasys, which is listed on The Nasdaq Stock Market under the ticker FEMY, will utilize the presentation in forthcoming discussions with investors, analysts, and other interested parties. The company, identified as an emerging growth company, has also chosen not to use the extended transition period for complying with new or revised financial accounting standards. The information provided in the presentation is for informational purposes and is not considered filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into any filings under the Securities Act of 1933, unless explicitly stated in such filings. Femasys's CEO, Kathy Lee-Sepsick, has signed off on the report, affirming the company's compliance with SEC requirements.
2024年4月24日，醫療技術公司Femasys Inc. 向美國證券交易委員會披露了一份監管文件，表明將發佈最新的公司簡報。該演示文稿現已在公司網站上公佈，作爲附錄99.1附在8-K表報告中。在納斯達克股票市場上市，股票代碼爲FEMY的Femasys將在即將與投資者、分析師和其他有關各方的討論中利用該演講。該公司被認定爲新興成長型公司，也選擇不使用延長的過渡期來遵守新的或修訂後的財務會計準則。除非此類文件中明確說明，否則演示文稿中提供的信息僅供參考，就1934年《證券交易法》第18條而言，不被視爲已提交，也未以引用方式納入根據1933年《證券法》提交的任何文件中。Femasys首席執行官凱西·李·塞普西克簽署了該報告，確認該公司遵守了美國證券交易委員會的要求。
2024年4月24日，醫療技術公司Femasys Inc. 向美國證券交易委員會披露了一份監管文件，表明將發佈最新的公司簡報。該演示文稿現已在公司網站上公佈，作爲附錄99.1附在8-K表報告中。在納斯達克股票市場上市，股票代碼爲FEMY的Femasys將在即將與投資者、分析師和其他有關各方的討論中利用該演講。該公司被認定爲新興成長型公司，也選擇不使用延長的過渡期來遵守新的或修訂後的財務會計準則。除非此類文件中明確說明，否則演示文稿中提供的信息僅供參考，就1934年《證券交易法》第18條而言，不被視爲已提交，也未以引用方式納入根據1933年《證券法》提交的任何文件中。Femasys首席執行官凱西·李·塞普西克簽署了該報告，確認該公司遵守了美國證券交易委員會的要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息